The certification confirms that HypothesisTM products are scientifically proven to reduce Staphylococcus aureus bacteria while preserving the balance and diversity of the skin microbiome — a crucial step forward in microbiome-safe eczema care. HypothesisTM products achieve this precision through TPZ-01TM, a patented new enzyme that specifically targets Staphylococcus aureus without disrupting the rest of the skin's microbiome.
"Dermatologists have long known the role of Staph aureus in eczema, but until now there haven't been tools designed to target it directly," said Oliver Liu, Ph.D, co-founder of HypothesisTM and Topaz Biosciences. "Hypothesis fills this gap, and this independent certification from MyMicrobiome validates the innovation we bring to eczema care."
The microbiome-friendly HypothesisTM launch collection — including a hydrogel, spray, and therapy cream — will be available at www.hypothesis.bio on September 30. In July 2025, MyMicrobiome launched two new standards for eczema-prone skin, 27.10 for adults and 27.11 for infants.
